Such a selective advantage is provided also by expression of cytosolic retinaldehyde dehydrogenases such as ALDH1A1, which was shown to characterize AML cells driving relapse, and which are resistant to chemotherapy. This evidence concerns the gene ALDH1A1 and acute myeloid leukemia.